Welcome to BlogNotions' Life Sciences Blog

The BlogNotions Life Sciences Blog delivers a diverse series of perspectives provided by thought leaders in the life sciences industries. Presented by NetLine, this forum delivers compelling updates on the latest technological advances, discussions of research and findings, best practices for advancing education, implications for the future of various life sciences fields, and much more. Here you can find helpful information, ask questions, and collaborate freely.

BCL-2 inhibitor shows promise in AML patients

In continuation of my update on Venetoclax Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. Journal in Which the Study […]

Continue Reading

Drug Patent Expirations for May 25, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. LUXIQ (betamethasone valerate) Mylan Pharms Inc Patent number: 7,078,058 Expiration Date: May 24, 2017 STRATTERA (atomoxetine hydrochloride) Lilly Patent number: 5,658,590 Expiration Date: May 26, 2017 […]

Continue Reading

First investigational treatment for infantile-onset SMA shows promising results in clinical trial

A major milestone was reached when nusinersen, an investigational treatment for spinal muscular atrophy (SMA), was shown to significantly improve achievement of motor milestones in babies with infantile-onset SMA, according to an interim analysis of the double-blind, randomized, placebo controlled Phase 3 clinical trial called ENDEAR. Babies born with SMA, a genetic disorder affecting nerves […]

Continue Reading

Heron Therapeutics Announces FDA Approval of Sustol (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Heron Therapeutics, Inc. (NASDAQ:HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved Sustol (granisetron) extended-release injection. Sustol is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy […]

Continue Reading

Drugs designed to target nervous system could control inflammation in the gut, study shows

There’s a reason it’s called a gut feeling. The brain and the gut are connected by intricate neural networks that signal hunger and satiety, love and fear, even safety and danger. These networks employ myriad chemical signals that include dopamine, a powerful neurotransmitter most famous for its role in reward and addiction. Duke University researchers […]

Continue Reading

Where are Drugs Invented, and Why Does it Matter?

Globalization has disrupted many industries, initially shifting unskilled labor employment from high wage-cost industrialized nations to lower wage-cost emerging economies. There has been a trend toward moving increasingly skilled work away from industrialized nations, which raises the question−has innovative research and development been affected by globalization and why is the relocation of innovation much more […]

Continue Reading

Drug Patent Expirations for May 18, 2017

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. CAMBIA (diclofenac potassium) Depomed Inc Patent number: 6,974,595 Expiration Date: May 15, 2017 CAMBIA (diclofenac potassium) Depomed Inc Patent number: 7,482,377 Expiration Date: May 15, 2017 […]

Continue Reading

Antioxidant compound could be effective to combat immune rejection after islet transplantation

A team of researchers has found that doses of bilirubin help provide suppression of the immune response following islet transplantation in mouse models. Bilirubin also significantly decreased islet cell death after the cells had been isolated and undergone nutrient deprivation and hypoxic (low oxygen) stress. If applied, the results of the study are expected to […]

Continue Reading